Ismael Rufino

Mr. Ismael Rufino


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SRSílvia Rocha
Sílvia Rocha
Carina ProençaCarina Proença
Carina Proença
Alberto N. AraújoAlberto N. Araújo
Alberto N. Araújo
Marisa FreitasMarisa Freitas
Marisa Freitas
IRIsmael Rufino
Ismael Rufino
Eduarda FernandesEduarda Fernandes
Eduarda Fernandes
Background/Objectives: Obesity has reached pandemic proportions, with predictions suggesting that, by 2030, over 1.5 billion people will be affected. Pancreatic lipase (PL), the enzyme primarily responsible for the absorption of dietary lipids, presents a potential target for obesity management. However, while porcine pancreatic lipase (PPL) is commonly used as the enzyme source for screening potential inhibitors, its effect on human pancreatic lipase (HPL) is rarely reported. This work aimed to screen the inhibitory effects of a library of flavonoids with different functional groups on the activity of PL from the human pancreas (triacylglycerol acyl hydrolase, EC 3.1.1.3) and compare it to the effects of the porcine pancreas (type II, EC 3.1.1.3), establishing, whenever possible, a structure–activity relationship. Methods: The inhibitory effects of a library of 48 flavonoids with different hydroxy, glycosyl, rutinosyl, galloyl, and extended alkyl groups were evaluated against PPL and HPL. The kinetic parameters and inhibitory mechanisms of the most active flavonoids were determined, and in silico docking studies of the more potent flavonoids were also performed, using the active site of HPL. Results/Conclusions: Variations in enzyme catalytic activity were observed depending on the source of the enzyme. The inhibitory effect was particularly influenced by the presence of extended alkyl groups at the C-3 of the C-ring and the C2=C3 double bond of the C-ring and the presence of a pyrogallol group at the C-2′, C-3′ and C-4′ of the B-ring. Docking results showed a strong correlation between docking scores and observed inhibitory activities, highlighting the critical role of specific substituents on the flavonoid backbone in enhancing detailed interaction dynamics with key amino acids. Compounds 28, 29, and 30, with alkyl groups, showed the highest docking scores, interacting with residues HIS151, PHE215, ARG256, and HIS263. Further analysis also revealed that specific substituents improved pocket occupancy and formed additional interactions with residues TYR114, PRO180, ILE209, and PHE215, which are crucial for inhibition. These binding characteristics closely mimic those observed with orlistat, reinforcing their mechanistic similarities in inhibiting HPL and validating their inhibitory activities.

Verified
Journal Article
Open access
PDF file
SMSara Moura
Sara Moura
Silvia MarinSilvia Marin
Silvia Marin
IRIsmael Rufino
Ismael Rufino
Rita GuedesRita Guedes
Rita Guedes
MCMARTA CASCANTE
MARTA CASCANTE
Jorge A. R. SalvadorJorge A. R. Salvador
Jorge A. R. Salvador
A series of novel carnosic acid 1 derivatives incorporating urea moieties at the C-20 position was synthesized and evaluated for their antiproliferative activity against the HCT116 colorectal cancer cell line. Most derivatives demonstrated enhanced antiproliferative activity compared to that of carnosic acid 1. The most promising derivatives were tested in other colorectal cancer cell lines (SW480, SW620, and Caco-2), melanoma (A375), and pancreatic cancer (MiaPaca-2). Derivative 14 consistently demonstrated the highest activity across all tested cancer cell lines, showing selectivity for cancer cells over normal cells. Further investigation of the mechanism of action in SW480 cells revealed that compound 14 induced cell cycle arrest at the G0/G1 phase by downregulating CDK4 and CDK6. Molecular docking studies revealed that compound 14 established several interactions with key residues in the active site of CDK6. Additionally, compound 14 also reduced ROS production. In summary, our results strongly indicate that compound 14 has potential as a lead compound in the development of innovative anticancer drugs.

Verified
Journal Article
Open access
PDF file
IDInês Ferreira Dias
Inês Ferreira Dias
CGCatarina Guerreiro-Oliveira
Catarina Guerreiro-Oliveira
IMInês Melo-Marques
Inês Melo-Marques
SCSandra Morais Cardoso
Sandra Morais Cardoso
Rita GuedesRita Guedes
Rita Guedes
MSMaria Amélia Santos
Maria Amélia Santos
Neurodegenerative disorders (NDs), such as Alzheimer’s and Parkinson’s diseases (AD and PD), despite having different main neuropathological hallmarks, share several interconnected aetiologic mechanisms and lack effective disease-modifying treatments. The multifactorial nature of these diseases has encouraged the development of new drugs such as multi-target-directed ligands (MTDLs). In this work, an anti-AD drug (rivastigmine, RIV) was fused and conjugated with a series of antioxidant scaffolds to obtain a small library of RIV–antiox hybrids. In addition to inhibitory activity towards both cholinesterases, these hybrids exhibited radical scavenging activity, inhibition of Aβ aggregation, and neuroprotection against cell death induced in AD models. The relevant anti-AD properties already found for these hybrids challenged us to also assess their capacity to modulate and interfere with ROS-associated harmful dysfunctions, namely in the dysregulation of biometal ions (Fe3+, Cu2+, and Zn2+) and upregulation of monoamine oxidases (MAOs). In particular, the capacity of the hybrids for metal chelation and inhibition of Cu-induced Aβ aggregation and MAO isoforms was evaluated, as well as their neuroprotection capacity in cell models of PD. Overall, some of these RIV hybrids appear as lead compounds for the development of novel multifunctional agents against NDs.

22 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RFRita Felix
Rita Felix
LCLuis A. R. Carvalho
Luis A. R. Carvalho
IRIsmael Rufino
Ismael Rufino
Rita GuedesRita Guedes
Rita Guedes
AMAna Margarida Madureira
Ana Margarida Madureira
RMRui Moreira
Rui Moreira
Activity-based probes are indispensable tools for interrogating protease function, and quenched fluorescent variants enable dynamic, real-time imaging of enzymatic activity. Despite these advances, very few quenched activity-based probes (qABPs) have been reported for serine proteases, which constitute the largest and most diverse mechanistic class of proteases. β -Lactams have been extensively used to develop molecular tools and drugs designed to bind or be hydrolysed by serine-dependent bacterial enzymes. Here, we report the first monocyclic β -lactam-containing qABPs for detecting serine proteases. Both the enzyme-triggered activation mechanism and intrinsic reactivity of the probes were highly dependent on the relative position of the BODIPY-FL fluorophore and quencher moiety at the β -lactam core. qABPs displaying the most efficient turn-on mechanism were shown to selectively target human neutrophil elastase (HNE) in different human cell lysates. The most successful qABP was rapidly internalised and targeted HNE in U937 cells and human neutrophils. These results demonstrate the potential of the modular β -lactam warhead to develop turn-on probes to track neutrophil serine proteases in live cells

28 February 2025 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
NANatália Aniceto
Natália Aniceto
Nuno MartinhoNuno Martinho
Nuno Martinho
IRIsmael Rufino
Ismael Rufino
Rita GuedesRita Guedes
Rita Guedes
The Protein Data Bank (PDB) is an ever-growing database of three-dimensional macromolecular structures that has become a crucial resource for the drug discovery process. Exploring complexed proteins and accessing their associated ligands are essential for researchers to understand biological processes and design new compounds of pharmaceutical interest. However, currently available tools for large-scale ligand identification fail to address many of the more complex ways in which ligands are stored and represented in PDB structures. Therefore, a new tool called LigExtract was specifically developed for the large-scale processing of PDB structures and the identification of their ligands. This is a fully open-source tool available to the scientific community, designed to provide end-to-end processing. Users simply provide a list of UniProt IDs, and LigExtract returns a list of ligands, their individual PDB files, a PDB file of the protein chains interacting with the ligand, and a series of log files. These logs record the decisions made during the ligand extraction process and flag additional scenarios that might have to be considered during any follow-up use of the processed files (e.g., ligands covalently bound to the protein). LigExtract is freely available on GitHub (https://github.com/comp-medchem/LigExtract).